Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001422" target="_blank" >RIV/00064190:_____/25:10001422 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1002/clt2.70095" target="_blank" >https://doi.org/10.1002/clt2.70095</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/clt2.70095" target="_blank" >10.1002/clt2.70095</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)

Popis výsledku v původním jazyce

Background : Primary chronic rhinosinusitis (CRS) can be classified based on the sinuses involved and the dominant endotype of the mucosal inflammation. Since the introduction of type 2 targeted biologics as treatment option for CRS, assessment of the inflammatory status has gained importance in CRS patients. We here aimed to characterize CRS patients with and without elevated markers of type 2 inflammation. Methods : CRS patients who visited the outpatient ENT clinic in one of the 10 tertiary centers in 7 European countries were invited to use the Galenus Health mobile application for the monitoring of their disease. Results : CRS patients (n = 281) were stratified according to blood eosinophil counts or BEC (&lt; 150 cells/mu L: 21.6% of patients, &gt;= 150 cells/mu L: 78.4%; &lt; 250 cells/mu L: 36.3%, &gt;= 250 cells/mu L: 63.7%) and serum total IgE (&lt; 100 IU/mL: 59.9%, &gt;= 100 IU/mL: 40.1%). BEC and serum total IgE did not correlate well (Spearman r = 0.06; p = 0.39). CRS patients with BEC &gt;= 150 cell/mu L or &gt;= 250 cells/mu L, respectively, showed increased NPS, SNOT-22, VAS for total CRS symptoms, loss of smell, nasal blockage, runny nose compared to patients with BEC below 150 or 250 cells/mu L. CRS patients with increased serum total IgE (&gt;= 100 IU/mL) did not show differences in the outcome parameters compared to patients with levels below 100 IU/mL. CRS patients with asthma (58.9%) showed increased SNOT-22 and VAS loss of smell compared to patients without asthma. Conclusions : A significant proportion of CRS patients exhibit a type 2 endotype, characterized by blood eosinophilia (78%), increased serum total IgE (40%) and/or concomitant asthma (59%). Our results underline the usefulness of eosinophils as a marker of type 2 inflammation and severity but challenge the utility of serum total IgE since it does not correlate with any of the markers of severity.

Název v anglickém jazyce

Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)

Popis výsledku anglicky

Background : Primary chronic rhinosinusitis (CRS) can be classified based on the sinuses involved and the dominant endotype of the mucosal inflammation. Since the introduction of type 2 targeted biologics as treatment option for CRS, assessment of the inflammatory status has gained importance in CRS patients. We here aimed to characterize CRS patients with and without elevated markers of type 2 inflammation. Methods : CRS patients who visited the outpatient ENT clinic in one of the 10 tertiary centers in 7 European countries were invited to use the Galenus Health mobile application for the monitoring of their disease. Results : CRS patients (n = 281) were stratified according to blood eosinophil counts or BEC (&lt; 150 cells/mu L: 21.6% of patients, &gt;= 150 cells/mu L: 78.4%; &lt; 250 cells/mu L: 36.3%, &gt;= 250 cells/mu L: 63.7%) and serum total IgE (&lt; 100 IU/mL: 59.9%, &gt;= 100 IU/mL: 40.1%). BEC and serum total IgE did not correlate well (Spearman r = 0.06; p = 0.39). CRS patients with BEC &gt;= 150 cell/mu L or &gt;= 250 cells/mu L, respectively, showed increased NPS, SNOT-22, VAS for total CRS symptoms, loss of smell, nasal blockage, runny nose compared to patients with BEC below 150 or 250 cells/mu L. CRS patients with increased serum total IgE (&gt;= 100 IU/mL) did not show differences in the outcome parameters compared to patients with levels below 100 IU/mL. CRS patients with asthma (58.9%) showed increased SNOT-22 and VAS loss of smell compared to patients without asthma. Conclusions : A significant proportion of CRS patients exhibit a type 2 endotype, characterized by blood eosinophilia (78%), increased serum total IgE (40%) and/or concomitant asthma (59%). Our results underline the usefulness of eosinophils as a marker of type 2 inflammation and severity but challenge the utility of serum total IgE since it does not correlate with any of the markers of severity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CLINICAL AND TRANSLATIONAL ALLERGY

ISSN

—

e-ISSN

2045-7022

Svazek periodika

15

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

nestránkováno

Kód UT WoS článku

001567260300001

EID výsledku v databázi Scopus

2-s2.0-105014814996